Clinical trials
Vaccination clinical trials
Below are recruiting vaccination clinical trials, each written for real people, not researchers. We’re tracking 600 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07561723RecruitingPhase 1
IMP3 Vaccine for Advanced Lung Cancer After Treatment Failure
This study tests a new vaccine designed to help your immune system fight advanced lung cancer that has not responded to standard treatments. The vaccine targets a protein called IMP3 found in your cancer cells.
Chengdu, SichuanAges 18 years+ - NCT07565090RecruitingPhase 1
Sudan Virus Vaccine Safety Study for Healthy Adults
This study tests a new experimental vaccine designed to protect against Sudan virus, a rare but serious disease. Researchers will check if the vaccine is safe and helps your immune system fight off the virus.
Washington D.C., District of ColumbiaAges 18–50 - NCT07585370Recruiting
Long-term Safety and Effectiveness of Shingles Vaccine
This study follows up with people who received an experimental shingles vaccine (a live, weakened form of the virus) in a previous trial from 2020–2021. Researchers want to understand how well the vaccine continues to protect against shingles over time.
Nanjing, JiangsuAges 40 years+ - NCT07592260Recruiting
Nutrition supplements and vaccination uptake in rural Chad and Niger
This study tests whether giving nutrition supplements (SQ-LNS) to healthy young children increases vaccination rates and prevents malnutrition in rural communities in Chad and Niger. Researchers will also track children's health outcomes and interview families about their experiences.
Ngouri, Lac RegionAges 6 months–4.9 years - NCT07617376RecruitingPhase 4
Flu shot before leaving hospital after heart problems
This study tests whether giving a flu vaccine to patients before they leave the hospital after a heart condition improves their health. The vaccine may help protect your heart and prevent serious flu complications while you recover.
WroclawAges 18 years+ - NCT07636044Recruiting
Shingles Vaccine Response in Lupus Patients
This study tests how well the shingles vaccine (Shingrix) works in people with lupus who take immune-suppressing medications. Researchers want to understand if the vaccine provides good protection in lupus patients, since their immune systems work differently.
SeoulAges 50 years+ - NCT07660198RecruitingPhase 3
Pneumonia vaccine catch-up study for kids and teens
This trial tests a catch-up pneumococcal vaccine for children and adolescents who may have missed some doses. It aims to see how safe and effective the vaccine is in healthy kids aged 15 months to 17 years.
Birmingham, AlabamaAges 1.3 years–17 years - NCT07633197Enrolling by invitationPhase 1
Testing a new shingles vaccine for adults over 40
This study tests a new vaccine to protect against shingles (herpes zoster), a painful skin infection that can affect people as they age. You would receive the vaccine and be monitored to see if it's safe and how your body responds.
Zhengzhou, HenanAges 40 years+ - NCT07583160Enrolling by invitationPhase 1
YS247 Vaccine for Advanced Prostate Cancer
This trial tests a personalized cancer vaccine (YS247) designed to train your immune system to recognize and fight your prostate cancer. It may help slow or stop cancer growth in men whose cancer has spread and stopped responding to standard hormone treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07330440Enrolling by invitationPhase 1
MRNA vaccine study for preventing genital herpes
This study tests a new mRNA vaccine designed to protect against herpes simplex virus type 2 (HSV-2), the virus that causes genital herpes. It is for healthy adults who have not had a genital herpes outbreak in the last 6 months.
BeijingAges 18–55 - NCT07316361Enrolling by invitationEarly Phase 1
Personalized vaccine for high-risk endometrial cancer
This trial tests a personalized vaccine made from your tumor's unique proteins to help your immune system fight high-risk or advanced endometrial cancer. It is given along with your regular cancer treatments.
Thessaloniki, ThessalonikiAges Any age - NCT06078891Enrolling by invitationEarly Phase 1
BCG vaccine to lower Alzheimer's blood markers
This trial tests whether the BCG vaccine (a tuberculosis vaccine) can lower a blood marker linked to Alzheimer's disease. It is for people aged 70–80 who have slightly elevated p-tau181 levels but still have normal thinking and daily living skills.
JerusalemAges 70–80 - NCT03914768Enrolling by invitationPhase 1
Immune Cell Vaccine for Brain Tumors
This trial tests a vaccine made from immune cells (dendritic cells) designed to train your body to fight brain tumors like DIPG or glioblastoma. You may qualify if you have one of these tumors, have had standard treatment, and are generally healthy enough for the study.
Shenzhen, GuangdongAges 1–75 - NCT07158905RecruitingPhase 1
Tau vaccine study for early Alzheimer's prevention
This study tests a vaccine that targets tau protein, which is linked to Alzheimer's disease. It is for older adults who have no memory problems yet but have biological signs of early Alzheimer's, to see if the vaccine can prevent or slow down the disease.
Boca Raton, FloridaAges 65–80 - NCT07698600RecruitingPhase 1
Safety test of a new HIV vaccine in adults with or without HIV
This study tests a new RNA-based vaccine called BNT168 to see if it is safe and how the body responds to it. It is for healthy adults with or without HIV, and those with HIV will pause their regular treatment for a while during the study.
Houston, TexasAges 18–50 - NCT07777484RecruitingPhase 1
An Unblinded, Single Arm, Pilot Observational Study to Test the Safety, Tolerability, Immunogenicity and the Biological Effects of TRB-001 Vaccination in Individuals Who Have Previously Undergone aSyn Immunotherapy
ViennaAges 18 years+ - NCT02232191RecruitingPhase 2
Pneumonia vaccine immune response study after spleen injury
This trial studies how your immune system responds to a pneumonia (pneumococcal) vaccine after a spleen injury. It may help doctors better predict and improve protection in people recovering from splenic trauma.
Sacramento, CaliforniaAges 18–65 - NCT07722741RecruitingPhase 2
Vaccine to prevent liver cancer return after surgery
This trial tests a personalized vaccine plus a booster (IL-12) to see if it can stop liver cancer from coming back after surgery. It compares the vaccine to just watching and waiting.
Atlanta, GeorgiaAges 18 years+ - NCT07013487RecruitingPhase 3
Dengue vaccine study for healthy children ages 2 to 17
This trial tests an experimental dengue vaccine in healthy children and teens to see if it can prevent dengue. It may help protect your child from this mosquito-borne illness.
East Jakarta, Jakarta Special Capital RegionAges 2–17 - NCT06866405RecruitingPhase 3
RSV vaccine boost in a new pregnancy
This study tests whether a second dose of the RSV vaccine during a new pregnancy protects you and your baby from RSV. If you received the RSVpreF or Abrysvo vaccine in a past pregnancy, you may be able to join.
Birmingham, AlabamaAges birth+ - NCT06863142RecruitingPhase 1
Testing a new flu vaccine with or without adjuvant
This study tests a new investigational flu vaccine (FluMos-v2) with or without an adjuvant (ALFQ) to see how safe, tolerable, and effective it is. It may help protect against multiple flu strains.
Bethesda, MarylandAges 18–50 - NCT07758972RecruitingPhase 1
Gonorrhea vaccine safety study
This trial tests a new vaccine designed to protect against gonorrhea, a common sexually transmitted infection. The study checks how safe the vaccine is and how well it trains the immune system to fight the bacteria.
Neu-Ulm, BavariaAges 18–50 - NCT04936529RecruitingPhase 2
Vaccine plus β-glucan and GM-CSF for high-risk neuroblastoma
This trial tests a vaccine, combined with two other immune-boosting drugs (β-glucan and GM-CSF), to see if it can help keep neuroblastoma from coming back. It's for people who have already completed standard treatment and are in remission.
New York, New YorkAges Any age - NCT07737717RecruitingPhase 1
Testing an mRNA Ebola-Bundibugyo vaccine in healthy adults
This study tests a new mRNA vaccine (mRNA-1469) to prevent Ebola-Bundibugyo virus disease. It is for healthy adults to see if the vaccine is safe and produces an immune response.
Halifax, Nova ScotiaAges 18–65
Hear when a new Vaccination trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for vaccination?
- Yes. Clin2 currently lists 600 recruiting vaccination studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a vaccination trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a vaccination trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.